open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23
Get Citation

Metastatic non-small-cell lung cancer with EGFR mutation — case report

Marek Jasiówka, Ida Cedrych

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23

Abstract

A case of successful and prolonged treatment of metastatic lung cancer (adenocarcinoma) with the activating mutation of epidermal growth factor receptor gene, treated with erlotinib is presented. A caucasian 79 years old, never-smoker female was diagnosed with stage IV lung cancer in December 2012. A chest CT scan showed tissue mass 6 × 4 cm in size in the right lung with multiple metastases in both lungs. A biopsy revealed a histological subtype adenocarcinoma. As a first line of treatment she received 3 courses of cisplatin and pemetreksed. It was complicated by pulmonary embolism. Progression-free survival after first line treatment was 7 months. Due to disease progression in September 2013 second line treatment with erlotinib was started. First radiological assessment after two months treatment with erlotinib showed partial response of the disease. Patient still continues the treatment with a favourable response and without any adverse reaction.

Abstract

A case of successful and prolonged treatment of metastatic lung cancer (adenocarcinoma) with the activating mutation of epidermal growth factor receptor gene, treated with erlotinib is presented. A caucasian 79 years old, never-smoker female was diagnosed with stage IV lung cancer in December 2012. A chest CT scan showed tissue mass 6 × 4 cm in size in the right lung with multiple metastases in both lungs. A biopsy revealed a histological subtype adenocarcinoma. As a first line of treatment she received 3 courses of cisplatin and pemetreksed. It was complicated by pulmonary embolism. Progression-free survival after first line treatment was 7 months. Due to disease progression in September 2013 second line treatment with erlotinib was started. First radiological assessment after two months treatment with erlotinib showed partial response of the disease. Patient still continues the treatment with a favourable response and without any adverse reaction.

Get Citation

Keywords

lung cancer, adenocarcinoma, EGFR gene

About this article
Title

Metastatic non-small-cell lung cancer with EGFR mutation — case report

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

46-48

Published online

2015-03-23

Keywords

lung cancer
adenocarcinoma
EGFR gene

Authors

Marek Jasiówka
Ida Cedrych

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl